CBH:F:F-COLOPLAST SP.ADR 1/10 DK1 (EUR)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 12.4

Change

+0.10 (+0.81)%

Market Cap

USD 27.61B

Volume

50.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-17 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
IUI1:F Intuitive Surgical Inc

-2.05 (-0.47%)

USD 158.73B
ESLC:F ESSILORLUXOTTICA 1/2/O.N.

-3.00 (-2.88%)

USD 95.76B
ESL:F EssilorLuxottica Société ano..

-0.30 (-0.15%)

USD 95.72B
BOX:F Becton Dickinson and Company

-3.00 (-1.43%)

USD 61.57B
HYB0:F HOYA CORP. ADR/ 1 O.N.

-2.00 (-1.64%)

USD 42.88B
HYB:F HOYA Corporation

-1.65 (-1.33%)

USD 42.41B
RME:F ResMed Inc

-14.90 (-6.56%)

USD 33.80B
RMEA:F Resmed Inc DRC

-0.60 (-2.68%)

USD 33.02B
CBHD:F Coloplast A/S

-4.50 (-3.56%)

USD 27.31B
QS50:F STRAUM.HLD.UNSP.ADR/1/10

N/A

USD 20.01B

ETFs Containing CBH:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 21.57% 80% B- 80% B-
Dividend Return 0.71% 22% F 7% C-
Total Return 22.27% 67% D+ 71% C-
Trailing 12 Months  
Capital Gain 21.57% 72% C 73% C
Dividend Return 2.99% 60% D- 31% F
Total Return 24.56% 66% D+ 67% D+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 1.10% 56% F 48% F
Dividend Return 1.61% 47% F 44% F
Total Return 0.51% 41% F 21% F
Risk Return Profile  
Volatility (Standard Deviation) 6.52% 98% N/A 95% A
Risk Adjusted Return 24.77% 59% D- 53% F
Market Capitalization 27.61B 91% A- 93% A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.